Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.

ABSTRACT:

Purpose

To identify mechanisms and mediators of resistance to antiangiogenic therapy in human glioblastoma.

Experimental design

We carried out microarray gene expression analysis and immunohistochemistry comparing 21 recurrent glioblastomas progressing during antiangiogenic treatment with VEGF neutralizing antibody bevacizumab to paired pretreatment tumors from the same patients.

Results

Microarray analysis revealed that bevacizumab-resistant glioblastomas (BRG) had two clustering patterns defining subtypes that reflect radiographic growth patterns. Enhancing BRGs (EBRG) exhibited MRI enhancement, a long-established criterion for glioblastoma progression, and expressed mitogen-activated protein kinases, neural cell adhesion molecule-1 (NCAM-1), and aquaporin 4. Compar

SUBMITTER: DeLay M 

PROVIDER: S-EPMC3354006 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature